RxPG News XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!  

Medical Research Health Special Topics World
 
  Home
 
 Careers 
 Dental
 Medical
 Nursing
 
 Latest Research 
 Aging
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Psychiatry
 Public Health
 Radiology
 Rheumatology
 Surgery
 Urology
 Alternative Medicine
 Medicine
 Epidemiology
 Sports Medicine
 Toxicology
 
 Medical News 
 Awards & Prizes
 Epidemics
 Health
 Healthcare
 Launch
 Opinion
 Professionals
 
 Special Topics 
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate
 
 DocIndia 
 Reservation Issue
 Overseas Indian Doctor

Last Updated: May 20, 2007 - 10:48:48 AM
News Report
America Channel

subscribe to America newsletter
America

   EMAIL   |   PRINT
Ranbaxy gets FDA approval for allergy drug
May 19, 2007 - 11:50:22 AM
'This will further expand our product portfolio of affordable generic alternatives which have a favorable impact on the economics of the US healthcare system,' he said.

Article options
 Email to a Friend
 Printer friendly version
 America channel RSS
 More America news
[RxPG] Washington, May 19 - India's drug major Ranbaxy Laboratories has received tentative approval from the US Food and Drug Administration to manufacture and market a pill to treat rhinitis, one of the most common illnesses in the US.

Affecting more than 50 million people in US, rhinitis is marked by bouts of sneezing and itching, or a runny or stuffy nose that do not seem to go away.

Total annual market sales for the approved drug Fexofenadine Hydrochloride tablets were $931 million last year.

'We are pleased to receive this tentative approval for Fexofenadine Hydrochloride Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA,' said Jim Meehan, Vice President of Sales and Marketing for Ranbaxy Pharmaceuticals Inc - Friday.

'This will further expand our product portfolio of affordable generic alternatives which have a favorable impact on the economics of the US healthcare system,' he said.

Based in Jacksonville, Florida, RPI is a wholly owned subsidiary of Ranbaxy Laboratories Limited -, India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.





Related America News
Run to support fight against kidney disease
Mexican footballer banned for life for doping
Ranbaxy gets FDA approval for allergy drug
Sunita Williams assembles special space walk tool
Simpson misses charity benefit
Chronic pain may impair your memory
Silicon Valley companies provide technology for latest 'Shrek' film
Israel threatens to take 'other military actions' in Gaza
'World bank can now refocus on poverty in South Asia'
Microsoft buys ad-firm Aquantive for $6 bn

Subscribe to America Newsletter
E-mail Address:

 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
© All rights reserved 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us